ImmuCell Earnings
NASDAQ: ICCCHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 15, 4:00 PM ET · Delayed 15 min
Next earnings date
Thu, Nov 12, 2026
Fiscal period
Sep/2026
ImmuCell earnings summary
ImmuCell is scheduled to report Sep/2026 earnings on Nov 12, 2026. In its most recent report on Jul 9, 2026 (Q2 2026), ICCC posted EPS of $0.20. Revenue for the quarter was $7.2 million.
Quarterly EPS is up 233.3% from the same quarter a year earlier. Across the last 16 reports, ICCC shares moved an average of 4.3% (in either direction) in the first trading session after results, rising 9 times and falling 7 times.
Summary generated from market data by MetaCap's automated system. Methodology
ICCC earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Jul 9, 2026 | — | $0.20 | — | +2.2% |
| Apr 8, 2026 | — | $0.21 | — | +12.7% |
| Jan 8, 2026 | — | $-0.32 | — | -2.2% |
| Oct 7, 2025 | — | $-0.02 | — | -10.9% |
| Jul 9, 2025 | — | $0.06 | — | +2.2% |
| Apr 8, 2025 | — | $0.16 | — | +1.7% |
| Jan 10, 2025 | — | $0.09 | — | +6.0% |
| Oct 8, 2024 | — | $-0.09 | — | +2.2% |
| Jul 9, 2024 | — | $-0.20 | — | -3.3% |
| May 14, 2024 | — | $-0.06 | — | -5.6% |
| Apr 1, 2024 | — | $-0.15 | — | -2.9% |
| Nov 13, 2023 | — | $-0.12 | — | +0.8% |
| Aug 10, 2023 | — | $-0.18 | — | -0.2% |
| May 11, 2023 | — | $-0.30 | — | +4.3% |
| Mar 29, 2023 | — | $-0.22 | — | -3.7% |
| Nov 21, 2022 | — | $-0.08 | — | +7.9% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.